Breast ductal adenocarcinoma
MONDO:0005590A breast carcinoma arising from the ducts. While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive ductal carcinoma. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.
Also known as: duct adenocarcinoma, duct carcinoma, ductal adenocarcinoma, ductal carcinoma, breast ductal carcinoma, ductal breast adenocarcinoma, ductal breast carcinoma, ductal carcinoma of breast
2989 clinical trials for this condition and its sub-types, 19 tagged with Breast ductal adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Breast ductal adenocarcinoma
-
Ductal breast carcinoma in situ 152 trials
1 sub-type
-
Invasive ductal breast carcinoma 41 trials · 48 incl. sub-types
10 sub-types
- Basal-like breast carcinoma 5 trials
- Invasive tubular breast carcinoma 5 trials
- Medullary breast carcinoma 2 trials
- Breast mucinous carcinoma 1 trial Sub-types →
- Breast secretory carcinoma 1 trial Sub-types →
- Acinic cell breast carcinoma 0 trials
- Glycogen-rich clear cell breast carcinoma 0 trials
- Invasive ductal and lobular carcinoma 0 trials
- Pleomorphic breast carcinoma 0 trials
- Scirrhous breast carcinoma 0 trials
-
Breast papillary carcinoma 1 trial
1 sub-type
- Solid papillary breast carcinoma 0 trials
-
Breast apocrine carcinoma 0 trials
Most studied deeper sub-types
-
New short radiation regimen aims to cut side effects in breast cancer treatment
Disease control Recruiting nowThis study is testing whether a shorter, higher-dose radiation treatment (APBI) given over just three days is safe and effective for women with early-stage breast cancer or DCIS who have had a lumpectomy. The goal is to see if this approach causes fewer or milder side effects com…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
Blood test could spare thousands from unnecessary breast cancer treatment
Disease control Recruiting nowThis study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could Pre-Surgery radiation zap breast cancer before it spreads?
Disease control Recruiting nowThis study compares standard surgery alone versus a short course of radiotherapy followed by surgery for women with ductal carcinoma in situ (DCIS), a very early form of breast cancer. The goal is to see if pre-surgery radiation can completely eliminate the cancer cells in the re…
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New radiation method may boost immune attack on tumors
Symptom relief Recruiting nowThis study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Early phase 1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC